Cell Therapy for Diabetic Foot Ulcers Moves Closer to Key Trial Milestone
FibroBiologics completes third manufacturing batch of CYWC628, a fibroblast cell therapy targeting diabetic wound healing, with interim data due Q3 2026.
Summary
FibroBiologics has finished producing a third batch of its experimental cell therapy, CYWC628, for a clinical trial targeting diabetic foot ulcers — a serious complication that can lead to amputation. The therapy is applied topically and uses donor fibroblast cells to potentially accelerate wound healing beyond current standard care. The batch meets strict manufacturing safety standards and, once cleared, will provide enough supply to complete the ongoing Phase 1/2 trial with doses to spare. The randomized, multicenter trial tests low and high doses of CYWC628 alongside standard care versus standard care alone over up to 12 weeks. Statistically significant interim results are expected in the third quarter of 2026, making this a near-term development worth watching for anyone interested in regenerative medicine and diabetes-related complications.
Detailed Summary
Diabetic foot ulcers are one of the most serious and costly complications of diabetes, frequently leading to infection, hospitalization, and limb amputation. Current wound care treatments often fall short, leaving patients with slow-healing or non-healing wounds. FibroBiologics is developing CYWC628, a topically applied cell therapy using donor fibroblast cells, with the aim of dramatically improving healing outcomes for this vulnerable population.
The company has now completed manufacturing of a third batch of CYWC628 under current Good Manufacturing Practice (cGMP) standards — the regulatory benchmark for pharmaceutical production quality and safety. The batch is undergoing mandatory safety and quality testing before being released for clinical use. Completing this production milestone means the trial will have sufficient drug supply to run to completion, along with surplus doses retained for future research.
CYWC628 is being evaluated in a multicenter, randomized Phase 1/2 clinical trial. Participants receive either standard wound care alone or standard care combined with low or high doses of CYWC628 for up to 12 weeks. The trial is assessing safety, tolerability, and early efficacy signals. Preclinical data from the company suggest the therapy may outperform existing treatments in accelerating wound closure, though human evidence remains pending.
A key upcoming milestone is the anticipated release of statistically significant interim data in Q3 2026. This will offer the first meaningful human evidence of whether CYWC628 delivers on its preclinical promise. Eliminating the need for further manufacturing also provides near-term cost savings for the company.
Important caveats apply: this is still early-stage clinical research, and interim data from a Phase 1/2 trial does not constitute proof of efficacy. Independent peer review and larger trials would be needed before this therapy could change clinical practice. Still, for those tracking regenerative medicine and diabetes complications, this is a meaningful step forward.
Key Findings
- Third cGMP-compliant batch of CYWC628 fibroblast cell therapy completed for diabetic foot ulcer trial.
- Supply now sufficient to complete the Phase 1/2 trial with surplus doses held for future R&D.
- Statistically significant interim trial data expected in Q3 2026.
- Therapy is topically applied using donor fibroblast cells to stimulate wound healing.
- Preclinical data suggest CYWC628 may accelerate healing versus current standard-of-care treatments.
Methodology
This is a news report summarizing a company announcement from FibroBiologics, not a peer-reviewed study. Evidence basis is preclinical data and ongoing trial design; no human efficacy results have been published yet. Source credibility is moderate — Longevity.Technology is a reputable health and longevity news outlet, but the underlying data comes directly from the company.
Study Limitations
All efficacy claims are currently based on preclinical data; human trial results are pending. This is a company announcement and may reflect optimistic framing; independent verification of trial outcomes is essential. Phase 1/2 trials are primarily designed for safety and early signal detection, not definitive efficacy proof.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: